St. Louis, Missouri: Largest U.S. center of excellence for single-use technology in biologics manufacturing

Video

In 2021, Thermo Fisher Scientific completed an $82.5 million expansion at our biologics site in St. Louis, Missouri, adding two manufacturing suites and $15 million in upgraded equipment, including the DynaDrive™ HyPerforma™ 5,000 L Single-Use Bioreactor (S.U.B.), to support large-scale production. The expansion more than doubled the site’s overall capacity to develop and commercialize specialized treatments for a variety of conditions and rare diseases that compromise the immune system, establishing it as the largest single-use technology (S.U.T.) CDMO facility in the United States.

Watch the video to learn more about the site expansion.

Read about the benefits of S.U.T.—from increased sustainability and reduced costs to accelerated timelines and higher production efficiency—with these helpful resources:

The benefits of 5,000L single-use bioreactors for biologics manufacturing

This whitepaper outlines how to evaluate capacity needs and the benefits of using single-use bioreactors (SUBs) at different drug development stages in biologics manufacturing.

Sustainable systems: Evaluating the environmental impact of single-use biomanufacturing technology

This whitepaper explores the advantages of sustainability with respect to single-use bioreactors, buffer and media hold containers, centrifuges and other biomanufacturing equipment.

5,000L single-use bioreactors: The next generation in biologics manufacturing

As the global biologics market and scientific advancements in biopharmaceuticals continues to rise, so has the demand for therapeutics, expanding indications for biologics, and the growing portfolios of biosimilars.

Multiplexing: Managing risk with proven, single use solutions

When pharmaceutical companies introduce a new drug to market, they invest enormous amounts of capital, and assume equally enormous amounts of risk.

Ready to discuss your project?

Connect with us